$1.30
-0.10[-7.14%]
At close: May 9
$1.30
0[0.00%]
After Hours: 7:57PM EDT
Akebia Therapeutics
(NASDAQ:AKBA)Latest News for Akebia Therapeutics Stock (NASDAQ:AKBA)
Akebia Therapeutics Stock (NASDAQ: AKBA)
Categories: All
Thursday, May 09, 2024
Wednesday, April 10, 2024
Friday, March 29, 2024
Thursday, March 28, 2024
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - Mar 28, 2024, 1:35PM
- HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6Benzinga Newsdesk - Mar 28, 2024, 12:20PM
- FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated AnemiaVandana Singh - Mar 28, 2024, 9:50AM
- Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 28, 2024, 8:21AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Mar 28, 2024, 8:06AM
- Akebia Therapeutics shares are trading higher after the FDA approved Vafseo tablets for treatment of anemia due to chronic kidney disease in adult patients on dialysis.Benzinga Newsdesk - Mar 28, 2024, 7:24AM
- Reported Earlier, Akebia's Wins FDA Approval Of Vafseo® Tablets For Dialysis-Related Anemia TreatmentBenzinga Newsdesk - Mar 28, 2024, 1:51AM
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Friday, March 15, 2024
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Mar 15, 2024, 1:31PM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Mar 15, 2024, 9:06AM
- HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $5 Price TargetBenzinga Newsdesk - Mar 15, 2024, 6:27AM
Thursday, March 14, 2024
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Mar 14, 2024, 5:33PM
- Recap: Akebia Therapeutics Q4 EarningsBenzinga Insights - Mar 14, 2024, 5:25PM
- Akebia Therapeutics Q4 Sales $56.200M Beat $55.393M EstimateBenzinga Newsdesk - Mar 14, 2024, 4:36PM
- Earnings Scheduled For March 14, 2024Benzinga Insights - Mar 14, 2024, 5:52AM
Wednesday, March 13, 2024
Tuesday, January 30, 2024
Wednesday, November 29, 2023
Friday, November 17, 2023
Wednesday, November 08, 2023
- Akebia Therapeutics Reaffirms FY23 Net Product Revenue Guidance Of $170M - $175M For AuryxiaBenzinga Newsdesk - Nov 8, 2023, 7:42AM
- Akebia Therapeutics Q3 EPS $(0.08), Inline, Sales $42.05M Miss $48.18M EstimateBenzinga Newsdesk - Nov 8, 2023, 7:33AM
- Earnings Scheduled For November 8, 2023Benzinga Insights - Nov 8, 2023, 4:21AM
Tuesday, November 07, 2023
Wednesday, October 25, 2023
Thursday, September 28, 2023
Wednesday, September 27, 2023
Tuesday, September 26, 2023
- Akebia Lowered Auryxia Product Revenue Guidance To $170M-$175M For FY23 From $175M-$180M Due To An Unfavorable Impact From Market Dynamics, Volume And Payor MixBenzinga Newsdesk - Sep 26, 2023, 8:17AM
- Australia's Therapeutic Goods Administration Has Approved Akebia Therapeutics' Vafseo (Vadadustat) For Anemia Associated With Chronic Kidney Disease In Adults On Chronic Maintenance DialysisBenzinga Newsdesk - Sep 26, 2023, 8:15AM
Monday, August 28, 2023
- Analyst Highly Confident In Akebia Therapeutics' Kidney Disease-Associated Anemia Drug, Stock SoarsVandana Singh - Aug 28, 2023, 2:31PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Aug 28, 2023, 1:31PM
- Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023Benzinga Insights - Aug 28, 2023, 11:00AM
- HC Wainwright & Co. Upgrades Akebia Therapeutics to Buy, Raises Price Target to $3.75Benzinga Newsdesk - Aug 28, 2023, 6:30AM
Friday, August 25, 2023
- Akebia Has Affirmed Its 2023 Auryxia Net Product Revenue Guidance Of $175M-$180MBenzinga Newsdesk - Aug 25, 2023, 8:13AM
- Akebia Therapeutics Q2 EPS $(0.06) Misses $(0.02) Estimate, Sales $56.38M Miss $59.10M EstimateBenzinga Newsdesk - Aug 25, 2023, 8:11AM
- Earnings Scheduled For August 25, 2023Benzinga Insights - Aug 25, 2023, 7:39AM
- Intuit, Hibbett And 3 Stocks To Watch Heading Into FridayLisa Levin - Aug 25, 2023, 4:25AM
- Fear & Greed Index Moves To 'Fear' Zone Ahead Of Powell's SpeechLisa Levin - Aug 25, 2023, 2:54AM
Thursday, August 24, 2023
Friday, August 11, 2023
- Akebia Therapeutics shares are trading lower after the company announced the late filing of its Q2 earnings and Form 10Q but reaffirmed its FY23 net product revenue guidance.Benzinga Newsdesk - Aug 11, 2023, 12:36PM
- HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $2 Price TargetBenzinga Newsdesk - Aug 11, 2023, 6:50AM
Thursday, August 10, 2023
- Akebia Expects To Resubmit NDA For Vadadustat As Treatment For Anemia Due To CKD In Adult Patients On Dialysis In Q3 2023Benzinga Newsdesk - Aug 10, 2023, 5:50PM
- Akebia Therapeutics Reports Late Filing Of Its Q2 Earnings And Form 10-Q; Reaffirms 2023 Net Product Revenue Guidance Of $175M-$180MBenzinga Newsdesk - Aug 10, 2023, 5:49PM